TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-0.34%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
-$21.2M
(-0.8%)
Cap. Flow
+$36.2M
Cap. Flow
% of AUM
1.38%
Top 10 Holdings %
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13
Top Buys
| 1 |
Elevance Health
ELV
|
$45.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$22.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$19.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$18.2M |
| 5 |
Exelixis
EXEL
|
$14.1M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$47.2M |
| 2 |
Stryker
SYK
|
$26.4M |
| 3 |
Zimmer Biomet
ZBH
|
$24.7M |
| 4 |
Lantheus
LNTH
|
$21.7M |
| 5 |
Humana
HUM
|
$19.9M |
Sector Composition
| 1 | Healthcare | 96.54% |
| 2 | Real Estate | 2.01% |
| 3 | Industrials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alnylam Pharmaceuticals
ALNY
$59.6B
| $28.7M | 1.09% |
143,214
| – | – |
|
27
Boston Scientific
BSX
$160B
| $28.3M | 1.08% |
565,990
-191,025
| -25% | -$9.56M |
|
28
Medtronic
MDT
$120B
| $27.8M | 1.06% |
344,517
+18,345
| +6% | +$1.48M |
|
29
Danaher
DHR
$141B
| $26.6M | 1.01% |
119,218
| – | – |
|
30
DexCom
DXCM
$31.9B
| $26.6M | 1.01% |
228,747
+10,732
| +5% | +$1.25M |
|
31
Charles River Laboratories
CRL
$7.95B
| $23.8M | 0.91% |
118,083
+45,408
| +62% | +$9.16M |
|
32
McKesson
MCK
$86.3B
| $23.7M | 0.9% |
66,455
| – | – |
|
33
HCA Healthcare
HCA
$97.1B
| $23.4M | 0.89% |
88,703
-16,300
| -16% | -$4.3M |
|
34
Zoetis
ZTS
$67.5B
| $22.8M | 0.87% |
136,914
| – | – |
|
35
Jazz Pharmaceuticals
JAZZ
$7.8B
| $21.6M | 0.82% |
147,779
-35,003
| -19% | -$5.12M |
|
|
36
Stryker
SYK
$151B
| $20.4M | 0.78% |
71,578
-92,550
| -56% | -$26.4M |
|
|
37
Humana
HUM
$37.4B
| $17.9M | 0.68% |
36,794
-40,919
| -53% | -$19.9M |
|
38
Novo Nordisk
NVO
$250B
| $17.7M | 0.67% |
222,646
-38,400
| -15% | -$3.06M |
|
39
Molina Healthcare
MOH
$9.13B
| $16.5M | 0.63% |
61,856
-11,759
| -16% | -$3.15M |
|
40
ResMed
RMD
$39.9B
| $16M | 0.61% |
73,189
+12,490
| +21% | +$2.74M |
|
41
Edwards Lifesciences
EW
$47.4B
| $14.2M | 0.54% |
171,146
-242
| -0.1% | -$20K |
|
|
42
Exelixis
EXEL
$9.94B
| $14.1M | 0.54% |
+726,639
| New | +$14.1M |
|
43
United Therapeutics
UTHR
$17.2B
| $13.7M | 0.52% |
61,200
-53,877
| -47% | -$12.1M |
|
44
Acadia Healthcare
ACHC
$2.17B
| $13.5M | 0.51% |
186,487
+45,298
| +32% | +$3.27M |
|
45
Ascendis Pharma
ASND
$12.1B
| $13.3M | 0.51% |
123,791
| – | – |
|
46
uniQure
QURE
$941M
| $13.1M | 0.5% |
652,446
| – | – |
|
|
DOC
47
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $13M | 0.5% |
873,655
+704,914
| +418% | +$10.5M |
|
48
BioNTech
BNTX
$24.6B
| $12.9M | 0.49% |
103,858
| – | – |
|
49
IQVIA
IQV
$30.9B
| $12.6M | 0.48% |
63,117
| – | – |
|
50
Novartis
NVS
$249B
| $12.5M | 0.48% |
136,225
| – | – |
|